Reports Q3 revenue $83.52M, consensus $82.9M. "This quarter reinforced our view about how a unique, innovative technology combined with disciplined execution can drive a differentiated financial profile in molecular diagnostics," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne. "The incredible strength and momentum across our prenatal and oncology businesses reflects a deliberate commitment to scientific rigor paired with resourceful, step-by-step execution. We continue to earn the trust of providers, patients, payors, and health systems, and rapidly grow our test volumes by solving unmet clinical needs. As we begin our path as a public company, we remain guided by the same principles we started with-relentless focus and an unwavering commitment to re-defining molecular diagnostics."
Wall Street analysts forecast BTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast BTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 36.220
Low
Averages
High
Current: 36.220
Low
Averages
High
Guggenheim
NULL -> Buy
initiated
$120
Al Analysis
2026-01-06
Reason
Guggenheim
Price Target
$120
Al Analysis
2026-01-06
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of BillionToOne with a Buy rating and $120 price target.
JPMorgan
Casey Woodring
Overweight
downgrade
$150 -> $145
2025-12-10
Reason
JPMorgan
Casey Woodring
Price Target
$150 -> $145
2025-12-10
downgrade
Overweight
Reason
JPMorgan analyst Casey Woodring lowered the firm's price target on BillionToOne to $145 from $150 and keeps an Overweight rating on the shares. The company reported solid Q3 sales and EBIT results, the analyst tells investors in a research note. The firm says the earnings print contains with few surprises.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BTO
Unlock Now
BofA
Lawson Winder
Underperform
maintain
$6
2025-11-24
Reason
BofA
Lawson Winder
Price Target
$6
2025-11-24
maintain
Underperform
Reason
BofA analyst Lawson Winder raised the firm's price target on John Hancock Bank & Thrift Opportunity Fund to $6.25 from $6 and keeps an Underperform rating on the shares. The firm is refreshing its price forecasts for North American Metals & Mining stocks under its coverage, the analyst tells investors. The firm sees the macro backdrop as challenging due to China's slowing commodity demand but notes this may be offset by a rebound in demand in U.S. and Europe.
BofA
Lawson Winder
Underperform
downgrade
$6
2025-11-24
Reason
BofA
Lawson Winder
Price Target
$6
2025-11-24
downgrade
Underperform
Reason
BofA analyst Lawson Winder lowered the firm's price target on John Hancock Bank & Thrift Opportunity Fund to $6 from $6.25 and keeps an Underperform rating on the shares. The firm is refreshing its price forecasts for North American Metals & Mining stocks under its coverage, the analyst tells investors. The firm sees the macro backdrop as challenging due to China's slowing commodity demand but notes this may be offset by a rebound in demand in U.S. and Europe.
About BTO
John Hancock Financial Opportunities Fund (the Fund) is a closed-end management investment company. The Fund's primary investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. Under normal circumstances, the Fund invests at least 80% of its net assets in equity securities of United States (U.S.) and foreign financial services companies of any size. These companies may include, but are not limited to, banks, thrifts, finance and financial technology companies, brokerage and advisory firms, real estate-related firms, insurance companies and financial holding companies. The Fund may invest up to 20% of its total assets in common and preferred equity securities and other preferred securities of foreign banking, lending and financial services companies, including securities quoted in foreign currencies. The Fund's investment adviser is John Hancock Investment Management LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
